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The human gastrointestinal tract is home to immense and complex populations of microorganisms. Using re-
cent technical innovations, the diversity present in this human body habitat is now being analyzed in detail.
This review focuses on the microbial ecology of the gut in inflammatory bowel diseases and on how recent
studies provide an impetus for using carefully designed, comparative metagenomic approaches to delve into
the structure and activities of the gut microbial community and its interrelationship with the immune system.Introduction
Our lives are deeply embedded within a microbe-dominated
world. Microbes drive many global geochemical cycles that ul-
timately provide us with oxygen, food, and water (Committee
on Metagenomics, 2007). On a more intimate level, diverse mi-
crobial communities assemble, and persist, on the external
and internal surfaces of our bodies from the time of our birth
until our death (after which time they proceed to consume
us!). Our gastrointestinal tract is home to the vast majority of
these microorganisms and their viruses. These microbes be-
long to all three domains of life on Earth—Bacteria, Archaea,
and Eucarya—and outnumber our own human cells by an or-
der of magnitude (Savage, 1977). This more transcendent per-
ception of ourselves has given rise to the view that we are
actually ‘‘supraorganisms’’ whose genome is the sum of genes
in our H. sapiens genome and the genomes of ‘‘our’’ microbial
partners (microbiome), and whose metabolic features are the
sum of human and microbial attributes (Gill et al., 2006; Turn-
baugh et al., 2006, 2007).
Most of the details concerning our gut microbiota remain ob-
scure. The factors that impact its assembly, and that define the
spatial distribution of its component members, are largely un-
known. In addition, the manner in which the composition and
metabolic operations of this microbial ‘‘organ’’ are regulated
and how its functional stability is maintained in the face of varied
environmental exposures in a persistently perfused ecosystem
are ill defined. The impact of our modern lifestyles—ranging
from our highly synthetic cookery to our use of broad-spectrum
antibiotics beginning at early stages of postnatal life—on the gut
microbiota is the subject of active conjecture, but only modest
amounts of hard experimental data.
This situation should change rapidly in the coming decade as
the recently launched international human microbiome project
delves into our gut microbial ecology in health and disease.
This project is being propelled by a number of forces (Turnbaugh
et al., 2007). They include an evolution in the focus of microbiol-
ogy from exploring the properties of microbial species in isolation
to characterizing their properties in the context of their naturalcommunities and habitats. In addition, the advent of massively
parallel DNA sequencers has dramatically increased the speed
of sequencing, markedly reduced its cost, expanded the ability
to characterize multiple samples simultaneously (Hamady
et al., 2008), and helped to democratize (distribute) the process
by which hypothesis-directed projects are designed and exe-
cuted by investigators within their own labs, as well as in partner-
ship with larger genome sequencing centers. One consequence
of this change in DNA sequencing capacity has been to spawn
a new area of science known as metagenomics. Metagenomics
refers to culture-independent studies of the structures and func-
tions of microbial communities, as well as their interactions with
the habitats they occupy (Committee on Metagenomics, 2007). It
includes sequencing of microbial DNA isolated directly from
a community occupying a given environment in order to deter-
mine its component microbial lineages and genes (the ‘‘micro-
biome’’), as well as characterizing the community’s expressed
RNA and protein products, and its metabolic network.
In this review, we focus on what culture-independent methods
are beginning to teach us about the microbial communities that
reside in the intestines of healthy individuals and those with in-
flammatory bowel diseases (IBD)—disorders that involve dys-
regulation of the homeostasis that is forged between our innate
and adaptive immune systems and our gut microbiota (Xavier
and Podolsky, 2007).
Surveys of the Human Gut Microbiota
Bacteria dominate the gut ecosystem. Much of this world is
terra incognita. The fact is that most organisms in complex
communities cannot be cultured ex vivo using today’s technol-
ogy. There is hope: new approaches for culturing previously
unculturable (gut) microorganisms are being developed (e.g.,
Duncan et al., 2007), as are methods for amplification and
sequencing genomic DNA from minute quantities of starting
materials (Marcy et al., 2007). In addition, current culture-inde-
pendent methods for surveying complex communities are more
accessible than ever, thanks to the marked increase in speed
and accompanying decrease in cost of DNA sequencing, andCell Host & Microbe 3, June 2008 ª2008 Elsevier Inc. 417
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the data stream.
Most of the culture-independent sequencing effort has been
directed toward small-subunit rRNA (SSU) genes, which are
present in all cellular organisms. 16S rDNA in Bacteria and
Archaea can be amplified directly by PCR from DNA isolated
from a sample that contains a microbial community—for exam-
ple, a mucosal biopsy or feces in the case of the gut. PCR reac-
tions use oligonucleotide primers that target highly conserved
regions of SSU rDNA (see Figure 1A) and therefore can amplify
rDNA from a broad range of organisms. Myriad SSU rDNA primer
sets have been devised, thus providing researchers with the abil-
ity to target virtually all or selected groups of organisms in a sam-
ple. The SSU rRNA gene was chosen for several reasons: it is rel-
atively small (1.5 kb), it has a high enough level of sequence
conservation between microbial species to permit reliable align-
ments, and it possesses sufficient variation to infer evolutionary
relationships. In addition, it is transmitted vertically within a line-
age rather than horizontally (between lineages).
The kinds of microbes present in a community specimen can
be identified by comparison of their SSU rRNA gene sequences
to previously analyzed sequences, including those from pheno-
typically and genetically well-characterized isolates. Depending
on the similarity of the newly isolated sequences to those in da-
tabases, microorganisms can be more or less precisely identi-
fied. By convention, but somewhat arbitrarily, SSU rRNA se-
quences with R97% identity (%ID) are considered to be from
the same ‘‘species,’’ while different species of the same genus
have R95%ID. More rigorous analyses, exemplified by infer-
ence from phylogenetic trees, can provide deeper insights into
the evolutionary relationships between newly identified taxa
and known relatives.
A cautionary note: although the %ID shared among rRNA se-
quences is typically used to define a given species, this definition
is a matter of some debate, largely because of lateral gene trans-
fer between different organisms. The result is that isolates of the
same ‘‘species,’’ as defined by rRNA phylogenetics, often differ
significantly in their collections of protein-coding genes. This fact
has prompted use of the term ‘‘pan-genome’’ to describe all
genes associated with all isolates of a ‘‘species’’-level phyloge-
netic type (phylotype) (Tettelin et al., 2005; Muzzi et al., 2007).
This fact has also evoked a provocative series of discussions
about how to best define a species (for example, should it be
a core set of signaling and/or metabolic pathways conserved be-
tween all isolates of that ‘‘species’’?) and conjured up an image
of the tree of life as having multiple connections between its
branches, giving it a more reticulated appearance (Doolittle
and Papke, 2006). Nonetheless, the rRNAs and most other ele-
ments of the nucleic acids-based genetic machinery have not
undergone lateral transfer and thus can be taken to indicate
true relationships reliably.
Despite these caveats about the meaning of the term ‘‘spe-
cies,’’ the richness or biodiversity in a microbial community can
be estimated by observing the number of new SSU rRNA se-
quences, binned into operational taxonomic units (OTUs) with
defined %ID cutoff thresholds, that appear with increased depth
of sampling (e.g., Figure 1B). Moreover, the degree of related-
ness of different communities can be quantified by constructing
a common phylogenetic tree composed of all SSU rRNA gene se-418 Cell Host & Microbe 3, June 2008 ª2008 Elsevier Inc.quences from all communities being analyzed. Pairwise compar-
isons of communities are then made based on the degree to
which they share branch length on this common tree (the ‘‘Uni-
Frac metric’’; Lozupone and Knight, 2005; Lozupone et al., 2006).
Figure 1. Bacterial SSU rRNA Gene-Based Surveys of the Gut
Microbiota
(A) Cartoon of the general structure of the bacterial 16S rRNA gene, showing
conserved and variable regions (based on http://www.rna.ccbb.utexas.edu/;
Cannone et al., 2002). Targets for PCR primers are shown. The numbers asso-
ciated with the primers are referenced to the E. coli 16S rDNA gene. The tar-
geted sites for PCR vary depending upon whether the goal is to sequence
the entire gene or subdomains containing variable regions. The read length
achievable with the current generation of massively parallel sequencers limits
the portion of the gene that can be characterized: currently favored regions are
V2–V3 (Hamady et al., 2008) and V6 (Huber et al., 2007).
(B) Analysis of diversity in the human gut microbial community based on sur-
veys of a limited number of humans. Collector’s curves of richness are shown.
16S rRNA gene sequences were ‘‘binned’’ into operational taxonomic units
(OTUs), which are widely assumed to represent ‘‘strain-level’’ taxa when the
OTU contains sequences withR99% pairwise sequence identity (%ID), ‘‘spe-
cies’’ when the %ID isR97%, ‘‘genus’’ atR95%ID, and ‘‘family’’ atR90%ID.
OTU richness is estimated as a function of the number of sequences obtained
and plotted for each OTU category. When a given curve begins to plateau, new
sequences are unlikely to yield new taxa. Note that the rate of discovery of new
strain-level OTUs remains steep throughout the range of sequences surveyed.
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Three reports describing the results of SSU rRNA gene se-
quence-based surveys of the distal small intestinal and colonic
microbiota of 139 adult humans living in North America illustrate
both the significant interpersonal variation and the similarities
that exist among our gut ecosystems (Eckburg et al., 2005; Ley
et al., 2006a, 2006b; Frank et al., 2007). These early returns
from what will soon be a global human gut survey indicate that
at the phylum level only a small fraction of known bacterial diver-
sity is represented in our guts: to date, members of only 10 out of
>100 described phyla have been identified. Furthermore, phy-
lum-level diversity is not evenly distributed. The majority of bac-
teria identified in all human guts surveyed belong to just two
phyla: the Firmicutes and the Bacteroidetes. On the other hand,
there is great diversity at lower taxonomic levels. In addition,
the accumulation of new taxa has not reached a plateau (Fig-
ure 1B). Moreover, there is considerable interpersonal variation
in the bacterial species and strains present in the gut microbiota
(Eckburg et al., 2005; Ley et al., 2006a, 2006b; Frank et al., 2007):
determination of the degree of variation awaits further sampling
of more individuals, as well as longitudinal studies of variation
within an individual over time. One challenge for this field is to dis-
cern the origins and biological implications of this variation. For
example, does it imply a large degree of functional redundancy
in the gene lineages and metabolic pathways represented in
the gut microbiome? Is it essential for maintaining the robust-
ness, or functional stability, of the gut community, i.e., its ability
to adapt to a variety of perturbations ranging from changes in
host diet, to the state of activation of the innate or adaptive im-
mune system, and/or to invasion by various pathogens?
Another challenge, raised by this observed interpersonal vari-
ation, is determining what constitutes a suitable reference control
when comparing the effects of various physiologic or pathologic
states on gut microbial ecology. A person is arguably his or her
best control. Therefore, a longitudinal (time course) study that
relates changes in an individual’s biology to microbial community
structure constitutes an attrative study design. However, this de-
mands that those involved in the international human microbiome
project devote considerable attention to characterizing the ex-
tent of intrapersonal variation that normally occurs in a microbiota
occupying in a given body habitat, including the gut. The possi-
bility exists that fluxuation in the proportional representation of
organismal lineages (defined by 16S rRNA surveys) is greater
than the representation of gene networks, embedded in the
microbiome, that encode various metabolic and other functions.
Legacy and Habitat Effects Shape the Gut Microbiota
How do we acquire our diverse gut microbiotas? In a pilot study
that used DNA fingerprinting, not sequencing, of rDNA ampli-
cons, Zoetendal et al. (2002) noted that the gut microbial com-
munities of monozygotic twins were more similar than between
twins and their unrelated marital partners. Moreover, Palmer
et al. (2007) utilized bacterial 16S rRNA-based detection
methods (DNA microarrays and sequencing) to profile the fecal
microbiota of 14 healthy full-term infants during their first year
of life. One pair of dizygotic twins was included in their study.
They found marked temporal variation in the composition of
the microbiota in the first few months of postnatal life. The pat-
tern of community assembly was most similar among the twins,lending strong support to the notion that early environmental ex-
posures (as well as genetic factors) play a major role in determin-
ing the distinctive characteristics of each baby’s microbiota.
These findings, together with the results of reciprocal microbiota
transplantation experiments involving transfer of gut microbial
communities from conventionally raised mice or zebrafish to
germ-free zebrafish or mouse recipients indicate that the com-
position of the gut microbiota reflects both legacy effects (a sum-
mation of the microbes we are exposed to after birth in our
distinctively experienced ecosystems), and habitat effects
(largely ill-defined ‘‘filters’’ that operate to select microbes for
residency in our different body sites) (Rawls et al., 2006). For ex-
ample, a role for the immune system and for host genotype was
provided by gas-liquid chromatography analysis of lipids ex-
tracted from the fecal microbiota of isogenic strains of C57Bl/6
mice that differ only at their major histocompatibility (MHC) lo-
cus, and in different inbred strains that were congenic for the
MHC: in the case of the former, fecal fatty acid profiles cluster
according to MHC genotype; in the case of the latter, host ge-
netic background effects are evident (Toivanen et al., 2001).
‘‘Where,’’ Not Just ‘‘Who’s There’’
The spatial or ‘‘biogeographic’’ features of the gut microbiota are
likely to have profound effects on microbe-microbe interactions,
including nutrient-sharing strategies that underlie syntrophic re-
lationships, and on microbe-host interactions, such as those
that affect the way in which microbes are recognized by compo-
nents of both the innate and adaptive immune systems. There-
fore, a great challenge for this field is to develop robust quanti-
tative methods to describe the distribution of phylotypes not
only along the length of the gut, but also across its width. By
width, we mean from the lumen and its collection of particulate
matter (undigested food fragments that can serve as nutrient
platforms, exfoliated epithelial cells, and mucus fragments; Son-
nenburg et al., 2005), across the mucus slime layer, to the epi-
thelium, which contains multiple cell lineages including resident
immune cells.
A systematic study of microbial populations sampled from
specified regions along the length of the human gut has yet to
be reported, although data have been obtained from subsets
of these regions in a given host—most notably, in the esopha-
gus and stomach (Bik et al., 2006), and in the distal small intes-
tine and colon (plus feces) (Eckburg et al., 2005; Frank et al.,
2007). The results reveal that the same bacterial phyla predom-
inate in the stomach, small intestine, and colon, although their
relative abundance and details of the component species vary
as a function of position along the gut’s cephalocaudal axis
(e.g., Figure 2).
Data obtained by Eckburg et al. (2005) indicated that mucosa-
associated communities sampled at different positions along the
length of the colon from a given individual differ from one an-
other, but not in a systematic manner between individuals. These
communities also differ from the fecal microbiota within an indi-
vidual (Eckburg et al., 2005). UniFrac analysis of these data sets
reveals that mucosal and fecal communities from a given individ-
ual cluster together, i.e., are more similar to one another com-
pared to samples taken at analogous sites from other hosts.
They also show that fecal samples can be used as a readily
(and safely) procured proxy for defining interpersonal differencesCell Host & Microbe 3, June 2008 ª2008 Elsevier Inc. 419
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intra- and interpersonal variation in the biogeography of the hu-
man gut microbiota is far from resolved. For example, a recent
report focused on distal small intestinal (ileal) and colonic muco-
sal biopsies obtained from 26 individuals who had not received
any bowel preparation or antibiotics prior to sample collection.
Using a combination of culture-independent methods (denatur-
ing gradient gel electrophoresis, quantitative PCR, and sequenc-
ing of 16S rRNA genes), Ahmed et al. (2007) observed that
communities occupying a given location along the length of the
distal gut clustered more closely between individuals than all
samples from a given host. These findings suggest that the
method used for bowel preparation is a very important clinical
parameter to note when interpreting such studies. Detailed
time course studies of spatial variation in gut microbial ecology
need to be performed in mice where potentially confounding
variables such as legacy effects (i.e., kinship relationships),
host genotype, diet, and methods used for harvesting and ma-
nipulating samples can be constrained.
Experiments conducted in germ-free mice colonized with
members of the human gut microbiota indicate that mucus
may be an important factor that influences the pattern of micro-
Figure 2. Bacterial Phyla Identified in the Human Gut Microbiota
Distribution of predominant bacterial phylotypes in the human intestinal tract.
The graphs depict relative abundance as a function of location along the ceph-
alocaudal axis of the distal gut. DNA sequences were compiled from the stud-
ies of Eckburg et al. (2005) and Frank et al. (2007). Phylogenetic classifications
were made by parsimony insertion of aligned sequences into a 16S rRNA tree
provided by the Greengenes database (DeSantis et al., 2006), using ARB (Lud-
wig et al., 2004). Abbreviations: IBD, samples from patients with either Crohn’s
disease or ulcerative colitis (Frank et al., 2007); Normal, data from healthy
young adults from Eckburg et al. (2005) plus the non-IBD controls reported
in Frank et al. (2007); n.d., not done. A total of 18,405 16S rRNA sequences
were analyzed (5405 IBD, 13,000 normal).420 Cell Host & Microbe 3, June 2008 ª2008 Elsevier Inc.bial colonization of different regions of the gut, as well as main-
tenance of microbial community structure and function. The mu-
cosa is a glycan-rich source of nutrients that can be used by
saccharolytic members of the gut microbiota (Hooper et al.,
1999), especially during periods when the diet is depleted of
complex plant polysaccharides (Sonnenburg et al., 2005). (The
proteomes of mice and humans contain a very limited arsenal
of glycoside hydrolases [Sonnenburg et al., 2006] and therefore
they, and we, depend upon glycoside hydrolases encoded in the
gut microbiome to process common but otherwise indigestible
polysaccharide components of our diets.)
Studies of healthy adult humans have shown that at a coarse
level of resolution there are regional differences in mucus matrix
proteins, as well as differences in the types and amounts of gly-
cans incorporated into mucus (Smithson et al., 1997; Corfield
et al., 2001). Unfortunately, mucus- and epithelial surface-asso-
ciated glycans are notoriously challenging to harvest from differ-
ent regions of the gut in a precise way, and in sufficient quantities
for biochemical analysis. Host glycans are structurally complex
and varied, reflecting the combinatorial nature of glycan biosyn-
thesis and modification (including modification by components
of the microbiota). Although ‘‘glycophobia’’ (fear of glycan com-
plexity) is common among biologists, new and effective strate-
gies for collecting information about intra- and interpersonal var-
iations in mucus and epithelial glycans are very much needed.
Mice with genetically engineered defects in mucus production
(An et al., 2007; Heazlewood et al., 2008) could serve as attrac-
tive starting points for linking mucus glycan content with gut
microbial ecology (see below).
The Microbial Ecology of the Gut in IBD
A variety of mouse models of IBD, including animals with genet-
ically engineered defects in their immune system or mucus gly-
cans, that have been conventionally raised with a microbiota
and then treated with antibiotics, or who have been raised
germ free and then colonized with a gut microbiota from a healthy
donor, demonstrate that the presence of a microbiota is instru-
mental in eliciting pathology (for very recent examples, see Gar-
rett et al., 2007 and Kang et al., 2008; for a review of earlier stud-
ies, see Sartor, 2008; for an excellent general overview of IBD,
see Xavier and Podolsky, 2007). It is important to emphasize
that, although rodent models of colitis are generally dependent
on the presence of gut microbes, not all microbes elicit disease
(Kim et al., 2007; Stepankova et al., 2007; Dijkstra et al., 2007).
Several studies have documented marked alterations in the
gut microbiota of patients with IBD (Giaffer et al., 1991; Gophna
et al., 2006; Krook et al., 1981; Lepage et al., 2005; Mangin et al.,
2004; Manichanh et al., 2006; Van de Merwe et al., 1988; Prindi-
ville et al., 2004; Scanlan et al., 2006; Seksik et al., 2003). Frank
et al., 2007 recently described the results of a case-control study
of intestinal microbiology ecology in patients with Crohn’s dis-
ease and ulcerative colitis, and in non-IBD controls (predomi-
nantly individuals with cancer of the bowel). Small intestinal
and/or colonic biopsy specimens were obtained at surgery, lumi-
nal contents were removed, and tissue-associated communities
were surveyed by 16S rRNA gene sequencing (n = 68 Crohn’s
disease specimens; 61 ulcerative colitis specimens; and 61
non-IBD control samples obtained from 35, 55, and 34 patients,
respectively [Figure 2]).
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between disease states (i.e., Crohn’s disease versus ulcerative
colitis versus non-IBD ‘‘controls’’) when controlling for anatomic
site and pathologic state (p = 0.02 for 99% OTUs, p = 0.11 for
97% OTUs). Each sample was assessed for the presence or
absence of all of the OTUs and then analyzed using principal
components analysis (PCA) and hierarchical clustering. These
clustering methods do not rely on predefined categorization of
samples, such as into IBD and non-IBD groups: rather, they
identify components that explain the greatest amount of the var-
iability within the data set (although these components may be
sensitive to the specific metric chosen for clustering). Based
on the PCA, the authors classified the samples into two groups.
The major group, designated ‘‘normal,’’ contained virtually all of
the non-IBD samples (60/61), and the majority of the colitis sam-
ples. The second group, designated ‘‘IBD-specific,’’ was highly
enriched in IBD samples (24 of 68 Crohn’s disease samples,
16 of 61 ulcerative colitis samples, and only one of the 61 normal
samples). The bacterial lineage distributions in the two groups
differed significantly, regardless of taxonomic depth (p < 0.001
for OTUs with 99%, 97%, 95%, 90%, and 85%IDs). The IBD-
specific group had marked decreases in the representation of
two prominent constituents of the gut community: the Bacteroi-
detes and the Lachnospiraceae (group IV and XIVa Clostridia).
Whether diminution of these populations is a cause or conse-
quence of disease, and whether this altered community struc-
ture (dysbiosis) persists upon remission, or is a condition that
exists in susceptible individuals prior to developing manifest
IBD remain to be established. However, there was a significant
association between a clinical history of abdominal abscesses
and harboring an ‘‘IBD-specific’’ type of microbiota in patients
with Crohn’s disease (Frank et al., 2007). This suggests a testable
hypothesis: alterations in the representation of components of
the microbiota, such as the Bacteroidetes and Lachnosspira-
ceae or other phylotypes, may be biomarkers that help predict
disease predisposition, activity, severity, and responsiveness
to therapy.
Mucosa-Associated Microbial Communities and IBD
The importance of mucosal communities in disease pathogene-
sis has been highlighted by studies that use fluorescent in situ
hybridization (FISH) to examine the distribution of microbes at
the interface between the colonic epithelium and its overlying
mucus layer in patients with and without IBD. For example,
FISH analysis detected bacteria within, or penetrating, the
mucus layer more frequently in mucosal biopsies obtained from
patients with IBD compared to healthy controls (30% versus
3%, respectively) (Swidsinski et al., 2007). Other studies have
demonstrated both thinning of the mucus layer in patients with
ulcerative colitis, as well as alterations in mucus glycan content
(Pullan et al., 1994; Smithson et al., 1997). Together, these find-
ings suggest that IBD may be associated with more intimate con-
tact between members of the microbiota and the mucosa. This
concept is supported by recent studies in mice: animals unable
to manufacture core-3 containing O-glycans are highly suscep-
tible to colitis induced by treatment with dextran sodium sulfate
(An et al., 2007), while mice with mutations in the Muc2 gene
develop colitis spontaneously (Heazlewood et al., 2008).Probiotics and IBD
Studies have yet to identify an organism that fulfills Koch’s pos-
tulates for IBD—a fact consistent with the notion that IBD is gen-
erally associated with deranged relationships between a given
host and his/her gut microbial community, rather than with a sin-
gle member of that community. Nonetheless, it is intriguing that
amelioration of disease has been reported in some controlled
clinical studies involving administration of live microbial supple-
ments (probiotics) to patients with IBD. Examples include the use
of VSL-3, a mixture of eight bacterial strains (Bifidobacterium
breve, B. longum, B. infantis, Lactobacillus acidophilus, L. plan-
tarum, L. casei, L. bulgaricus, and Streptococcus thermophilus)
in patients with ileal pouch inflammation (pouchitis) (Gionchetti
et al., 2003; Mimura et al., 2004). Various probiotics have demon-
strated clinical efficacy in patients with ulcerative colitis but not
Crohn’s disease (Sartor, 2004).
The impact of these probiotic preparations on gut microbial
ecology, and on the functions of the gut microbiota, has not
yet been analyzed using metagenomic approaches, either during
or after administration. These approaches will have to be applied
to patient populations where factors such as antibiotic use, diet,
and other potential confounding variables are constrained prior
to, during, and after probiotic treatment. Proof-of-principle ex-
periments involving administration of probiotics to (gnotobiotic)
mouse models of colitis, where genetic and environmental fac-
tors can be initially controlled, should help guide clinical studies
(see below).
IgA and the Regulation of Host-Microbial Homeostasis
A role for IgA in shaping the gut microbiota has been studied for
quite some time (Baklien and Brandtzaeg, 1975; van der Waaij
et al., 1996). Classical work by John Cebra demonstrated that
members of the microbiota elicit production of specific IgAs in
the gut, although they vary in their ability to do so (Shroff et al.,
1995). Others have shown that innate immune system activation
is greater in the absence of adaptive immunity (Cash et al., 2006;
Keilbaugh et al., 2005; and Peterson et al., 2007), and that addi-
tion of B cells or immunoglobulin (serum) ameliorates the severity
of colitis in several animal models (Mizoguchi et al., 1996, 1997).
A number of potential mechanisms in principle could account for
this amelioration. For example, it could reflect decreased epithe-
lial interaction with antibody-coated bacteria because they are
trapped in the mucus, or a modified host response after bacteria
are transported across the M cell pathway and taken up by den-
dritic cells, or opsonization and destruction of the bacteria that
do translocate across the barrier (Martinoli et al., 2007; Kadaoui
and Corthesy, 2007) (Figure 3). In addition to decreasing host in-
nate responses to bacteria, IgA could also modulate colitis by
changing gut microbial composition. IgA is known to produce
changes in gut microbial ecology in conventionally raised mice
(Suzuki et al., 2004; Fagarasan et al., 2002). For example, two re-
cent reports have demonstrated that an enigmatic, uncultivated
bacterial species known as Segmented Filamentous Bacteria
(SFB; a member of the Firmicutes) is important, but not sufficient,
to induce colitis in mice (in these studies, colitis was induced by
transfer of effector CD4+ T cells in the absence of T regulatory T
cells). SFB are consistently enriched in IgA-deficient mice (Su-
zuki et al., 2004) and are powerful inducers of IgA (Talham
et al., 1999). Moreover, colonization of the gut with SFBCell Host & Microbe 3, June 2008 ª2008 Elsevier Inc. 421
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velopment of a mucosal IgA response is associated with de-
creased levels of SFB colonization, while passive transfer of
IgA immunity slows colonization (Jiang et al., 2001). It is easy
to imagine how a failure to generate an adequate IgA response
to SFB could lead to expansion of this phylotype and conse-
quently to the development or aggravation of colitis in genetically
predisposed mouse models. Unfortunately, there are no reports
describing the results of comprehensive culture-independent
surveys of gut microbial ecology in IgA deficient patients with
or without colitis.
A recent study, performed in gnotobiotic mice, provides addi-
tional and direct evidence that the IgA antibody response to
members of the gut microbiota helps establish a quiescent rela-
tionship with the host (Peterson et al., 2007). Hybridoma cells
that produce a naturally primed IgA specific for a carbohydrate
epitope present in the capsule of a prominent human gut-asso-
ciated bacterial symbiont, Bacteroides thetaiotaomicron, were
implanted into the dorsal subcutaneous tissue of germ-free
Rag1/ mice that lack functional T and B cells. In other words,
in this engineered mouse model there was a single antibody rep-
Figure 3. Host-Microbial Interactions
Affected by IgA Are Modulated as Result
of Stimulation of the Immune System
at Different Sites
Secretory IgA, antimicrobial peptides, and mucus
are among the factors that comprise the mucosal
barrier. The ability of different microorganisms to
develop resistance to these factors, or to degrade
mucus, will contribute to greater microbial pattern
recognition receptor-mediated signaling in epithe-
lial cells, dendritic cells (DCs), macrophages, and
B cells. Where these organisms prime the adaptive
immune system will depend on how far they can
penetrate the barrier, and where the host traffics
microbial cells and their antigens. Numbers in
the figure refer to the following processes. (1)
The simplest response loop may be the innate im-
mune system’s induction of IgA production in the
lamina propria: natural killer (NK) cells, DCs, epi-
thelial cell-derived cytokines (APRIL, IL-10, TGF,
and TNF, among others), and membrane-bound
receptors (e.g., CD40-CD40 ligand) induce IgA
production from recruited B cells. (2) Bacteria,
bound or unbound by IgA in the lumen, are actively
transported to Peyer’s patches and associated
lymphoid organs where T cell priming and help
are more likely. (3) DCs transport whole bacteria
and microbial antigens to mesenteric lymph nodes
where priming of T cells and B cells programs
them to home to the lamina propria, and where
IgA induction is favored. (4) Commensal microbes
(and invasive pathogens) are transported and
trapped by the innate immune system in the
spleen, where a systemic immune response is in-
duced (lymphocytes primed in the spleen are
less likely to home to the gut, and more likely to
switch to non-IgA subclasses).
ertoire of known specificity, and the gut
microbiota was reduced to a single (se-
quenced) bacterial species. When these
animals were colonized with a wild-type
strain of B. thetaiotaomicron, levels of
epitope expression were inversely corre-
lated with IgA levels (IgA levels reflected the biomass of im-
planted hybridoma cells). Moreover, when these Rag1/ hy-
bridoma-bearing (‘‘backpack’’) mice were gavaged with equal
numbers of isogenic wild-type epitope-positive, and mutant epi-
tope-negative strains of B. thetaiotaomicron, the presence of the
antibody resulted in a marked relative decrease in wild-type bac-
teria (Rag1/ animals without implanted hybridoma backpacks
served as reference negative controls). Whole-genome tran-
scriptional profiling of host and bacterial responses in Rag1/
mice colonized with just the wild-type strain revealed that, in
the absence of IgA, B. thetaiotaomicron elicits a more robust ox-
idative response from the innate immune system in the distal gut,
and then adapts by inducing a number of its genes involved in
metabolism of the oxidative products generated by the host.
The presence of IgA reduces intestinal proinflammatory signal-
ing (Peterson et al., 2007).
Together, these findings support the following conclusions: (1)
IgA responses function to help mediate tolerance to the micro-
biota; (2) host-microbial homeostasis in the gut depends on rec-
ognition of members of the microbiota by the adaptive immune
system; and (3) the adaptive immune system likely mandates422 Cell Host & Microbe 3, June 2008 ª2008 Elsevier Inc.
Cell Host & Microbe 3, June 2008 ª2008 Elsevier Inc. 423
Cell Host & Microbe
Reviewthat entrenched residents of the community (autochthonous
members) perpetually modify their surface epitopes. This latter
type of selective pressure may provide one explanation for the re-
markable strain-level diversity in the gut microbiota, and for why
diversification of surface carbohydrates may help promote a qui-
escent relationship with a microbial community that provides
benefits to the host. In this conceptualization of host-microbe
homeostasis, tolerance to the microbiota is predicated on im-
mune recognition of its members. The adaptive immune system
functions to maintain a ‘‘connection’’ with the gut microbiota by
preferentially generating responses to bacteria that continue to
stimulate the innate system. The result is that the host is able
to detect new bacterial phylotypes, ‘‘ignore’’ those that it has al-
ready encountered, and support greater diversity in the gut eco-
system without sacrificing the innate immune system’s neces-
sary role in maintaining a functional mucosal barrier.
One extrapolation of this concept is that IBD is a manifestation,
at least in part, of a failure to generate effective adaptive immune
responses to the resident gut microbiota. Such responses may
normally prevent presentation of microbial antigens to T cells
specific for members of the community (Kadaoui and Corthesy,
2007). This hypothesis is supported by the antibody response to
gut microbes documented in T cell receptor alpha / mice:
these responses change from polyclonal to oligoclonal as colitis
develops; passive transfer of Ig (serum) ameliorates disease
severity (Mizoguchi et al., 1996, 1997). These results suggest
that the presence of a diverse anti-gut microbial antibody reper-
toire is protective against colitis, and as the diversity of this rep-
ertoire decreases so does this protection.
This concept of host-microbe homeostasis has implications
for the immunologist and for the microbial ecologist. If IgA
responses to the microbiota are a key component of host-micro-
bial homeostasis in the gut, then understanding the pathway for
generating these responses is clearly necessary. Immunologists
already know that IgA production can occur without T cells (Mac-
pherson and Uhr, 2004), that class switching to IgA appears to
happen locally in the lamina propria (Fagarasan et al., 2001),
and that dendritic cells can directly help B cells class switch to
IgA, independent of T cells through TNF, iNOS, Blys, and APRIL
(Litinskiy et al., 2002; He et al., 2007; Tezuka et al., 2007). Thus,
the IgA responses to the microbiota are likely to be driven by lo-
cal phenomena and involve simple feedback loops: dendritic
(and epithelial) cells direct IgA production by B cells independent
of T cells until IgA levels are sufficient to block microbial stimula-
tion; the systemic immune system is bypassed unless the local
feedback loop is not successful in stopping activation (Figure 3).
It is reasonable to suppose that the local feedback loop that
results in IgA-mediated homeostasis is impacted by some of
the genetic polymorphisms that have been associated with coli-
tis, including those that affect IL23R and ATG16L. For example,
ATG16L forms a complex with ATG5: both are involved in au-
tophagy (Fujita et al., 2008). Studies of genetically engineered
mice with cell lineage-specific ATG5 deficiency have shown
that they have defects in the development of B1-B cells (Miller
et al., 2008), which have a primary role in production of IgA in
the gut mucosa (Kroese et al., 1996). IL-23 is an IL-12-like cyto-
kine known to effect immunoinflammatory responses through
induction of Th17 CD4+ T cells (McGovern and Powrie, 2007).
In the case of IL23R mutations, altered signaling is likely to affectCD4+ T cell differentiation and could lead to changes in Ig iso-
type switching, including derangements in the induction of
specific IgA responses to gut bacteria.
The implication for the microbial ecologist interested in IBD
pathogenesis is that it may not be adequate to simply search
for microbial phylotypes that are enriched or depleted in IBD. A
key to understanding disease pathogenesis may be to identify
defects in the antibody repertoire to microbial epitopes. Com-
parative metagenomic approaches may be helpful in testing
this hypothesis. However, as discussed below, there are signifi-
cant challenges, including the need to design and stage proof-
of-principle tests under carefully controlled circumstances in
both mice and humans.
Metagenomics and IBD: A Wish List for the Future
Future research about the role of the gut microbiota in defining
IBD risk, pathogenesis, and treatment strategies will continue
to depend upon the intersection of two discovery pipelines—
one involving mouse models, the other humans. In the case of
conventionally raised and gnotobiotic mice, an extraordinary
opportunity exists to address a number of the unanswered
questions alluded to above:
 The diversity and biogeography of the gut microbiota needs
tobedefinedat varying scales of resolution, along the length
and width of the gut under conditions where diet and host
genotype can be constrained. Key questions include (1)
the nature of the interactions of microbial consortia with cel-
lular components of the innate and adaptive immune sys-
tems; (2) the effects of engineered perturbations of the
innate and adaptive systems on the acquisition, spatial dis-
tribution, diversity, and stability of the gut microbiota (and
microbiome); (3) the impact of antibiotic and/or immuno-
suppressive therapy on microbial community structure in
mice with or without colitis (is the microbiota restored to
its original status following these interventions? if so, this
opens the door to the possibility of using microbial lineage
and gene biomarkers to define disease severity, remission,
and/or risk of relapse in patients); and (4) the short- and
long-term effects of probiotics on community ecology in dif-
ferent regions of the gut, and on the activity of components
of the immune system in mice with or without genetically en-
gineered perturbations that predispose to development of
colitis. These characterizations should be targeted to both
SSU rDNA sequences and the rest of the microbiome.
 Determine whether microbiota transplants from mouse do-
nors with colitis to germ-free recipients (either wild-type or
with mutations that sensitize the host to the development of
colitis) will produce disease in the recipient. If so, the phe-
notypic results need to be correlated with comparative
metagenomic studies of the harvested donor community
and the recipient’s community—the latter as a function of
time after transplant and in different regions of the recipi-
ent’s gut with or without disease. Continued development
of new algorithms for defining similarities and differences
between microbial communities are needed to interpret
the results of these experiments. This type of study could
lay the groundwork for functional assays of human micro-
bial communities in gnotobiotic mice.
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to transcriptional, proteomic, and metabolic analyses.
These are great challenges. For transcriptional profiling, in
the absence of validated DNA microarrays, there is a need
to develop reliable methods for reducing the representation
of rRNA in a community RNA sample so that expressed tag
(EST) sequencing of cDNAs can be conducted using mas-
sively parallel sequencers. For shotgun proteomic analy-
ses, technical and bioinformatic lessons need to be gleaned
from ongoing studies of environmental communities of
varying complexity (e.g., Lo et al., 2007). The formidable
task of identifying and classifying known proteins and new
protein families will be facilitated by generating more refer-
ence genome sequences from representatives of the phylo-
types present in a microbiota (one of the goals of the human
microbiome project) and from new gut microbiome data
sets. Reports of transcriptome-guided or shotgun metabo-
lomic studies of the gut microbiota in various mouse models
of the human gut microbiota are just beginning to appear
(Samuel et al., 2007; Li et al., 2008; Martin et al., 2008).
 Create a pipeline for characterizing the evolution of
microbe-associated carbohydrate epitopes in a model gut
ecosystem created in gnotobiotic mice with and without
engineered genetic manipulations of their immune systems;
expand this analysis to more complex communities. The
degree to which adaptive immune responses to surface
carbohydrate epitopes play a role in shaping diversity
within the microbiota and host-microbial homeostasis
needs to be explored further. For example, we know that
at least some members of the gut Bacteroidetes dedicate
a considerable percentage of their genomes to fashioning
surface carbohydrate epitopes (Xu et al., 2007; Krinos
et al., 2001; Fletcher et al., 2007) and that certain epitopes
have marked effects on the activity of the host immune
system (Mazmanian et al., 2005, 2008). Capsular polysac-
charides, O-antigens, and exopolysaccharides represent
a highly diverse group of surface epitopes that can be mod-
ified by transcriptional regulation as well as by lateral trans-
fer of glycosyltransferase genes (GT) (Coyne and Com-
stock, 2008; Comstock et al., 2000; Xu et al., 2007).
Unfortunately, surface glycan structures cannot be pre-
dicted based only on knowledge of the repertoire of GTs
present in a microbial species or microbial community.
Therefore, new methods are needed to characterize glyco-
biomes (genes encoding proteins and enzymes involved
in carbohydrate biosynthesis and degradation) and their
biochemical products. It is possible that some of these
products may be useful for diagnostic and therapeutic pur-
poses.
 Characterize the B and T cell repertoire through high-
throughput sequencing of the complementary determining
regions of their respective antigen receptors. Antigen
receptor repertoire diversity, which is based on gene seg-
ment combinatorial rearrangement in B and T cells, rivals
the complexity of the microbial community. Deep sequenc-
ing of these genes should catalyze efforts to associate
microbial communities with defined antigen receptor rep-
ertoires. This notion is not far-fetched: Hsieh et al. (2004)
have already shown that by using a genetically ‘‘confined’’424 Cell Host & Microbe 3, June 2008 ª2008 Elsevier Inc.mouse model and conventional capillary DNA sequencers,
T cell receptors associated with regulatory T cells could be
identified. By using the new generation of massively paral-
lel DNA sequencers, it should be possible to associate
components of the unrestricted antigen-receptor reper-
toires in multiple patients with differing genetic back-
grounds with their microbial community structures.
The other component of this envisioned intersecting pipeline
involves humans with IBD. Among the many directions that this
effort can take are the following:
 Characterize monozygotic twins discordant for IBD. Twins
who are discordant for pathophysiologic states, such as
IBD, provide a very attractive starting point for developing,
or testing, hypotheses about the relationships between
a gut microbiota/microbiome, host genotype, host pheno-
types, and disease pathogenesis. This is generally true of
other physiologic and pathophysiologic conditions, where
the phenotypically normal cotwin serves as a powerful ref-
erence control (e.g., Pietilainen et al., 2008). A key chal-
lenge is to develop safe and effective/reliable ways for
sampling mucosa-associated communities along the
length of the gut, in regions with and without active disease
and as a function of disease activity (with activity compre-
hensively defined by histopathologic criteria and by profil-
ing host gene expression in tissue samples using functional
genomic and/or proteomic approaches). In this study par-
adigm, longitudinal surveys of the affected twin during cy-
cles of relapse and remission that individual to serve as his/
her own control: the unaffected twin serves as an additional
reference control, as do other twin pairs.
A parallel effort is also needed that characterizes the gut
microbiota in unrelated individuals, over time and as a func-
tion of IBD activity and host genotype. Moreover, do probi-
otic formulations that exhibit efficacy in well-controlled
clinical trials alter the structure and operations of a gut mi-
crobiota? If so, how do these effects correlate with disease
activity in an individual, or groups of genetically identical or
similar individuals?
 Evaluate microbial biomarkers of disease status obtained
from studies of mouse models. As noted above, these
could be DNA, mRNA, protein, immune, metabolic, and/
or carbohydrate biomarkers. Finding suitable controls for
correlating disease activity with these candidate bio-
markers will be a challenge: given the interpersonal varia-
tions that have been noted in gut microbial ecology, must
an individual ultimately serve as his/her own control? A
goal for this type of analysis, and for the human microbiome
project in general, is to use these biomarkers as new ways
for defining health, disease susceptibility, disease status,
and responses to therapy.
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